Holdings
iShares Biotechnology ETF
As of Jun 30, 2026, iShares Biotechnology ETF reported 229 positions worth US$8.94B. Largest: Vertex Pharmaceuticals Incorporated, Amgen Inc. and Gilead Sciences, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | 1.48M | US$734M | +124K | Jun 30, 2026 |
| Amgen Inc. | 1.96M | US$711M | +231K | Jun 30, 2026 |
| Gilead Sciences, Inc. | 4.92M | US$622M | +406K | Jun 30, 2026 |
| Regeneron Pharmaceuticals, Inc. | 715K | US$446M | −43,172 | Jun 30, 2026 |
| Argenx Se | 368K | US$342M | +26,294 | Jun 30, 2026 |
| Alnylam Pharmaceuticals, Inc. | 942K | US$284M | −37,468 | Jun 30, 2026 |
| Natera, Inc. | 968K | US$263M | −12,939 | Jun 30, 2026 |
| Revolution Medicines, Inc. | 1.35M | US$253M | +65,206 | Jun 30, 2026 |
| Biogen Inc. | 1.04M | US$224M | −53,882 | Jun 30, 2026 |
| Illumina, Inc. | 1.07M | US$188M | −37,933 | Jun 30, 2026 |